Before patients can be treated with REGEN-COV2 under the EUA, they must weigh at least 40 kilograms (about 88 pounds) and be deemed at high risk for progressing to severe COVID-19 and/or hospitalization. That high-risk category includes adults who are ages 65 or older, or who have chronic medical conditions.
With some positive results in the clinic, there are other encouraging signs the field is maturing and branching into other therapeutic areas such as oncology.
From Mendelian disorders to COVID-19, academic and industrial scientists use these nucleic acids to help diagnose diseases.
In our second installment of women making their mark in the field, Clinical OMICs interviews Bonnie Anderson of Veracyte, Tina Hambuch of Invitae, and Cindy Perettie of Foundation Medicine.
California Medicaid’s pilot program Project Baby Bear delivers better outcomes at lower cost via rapid whole-genome sequencing of critically ill newborns.
A report from the Personalized Medicine Coalition found significant variability in the use of genomic testing for patients not only from state to state, but also within states.